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Aims We investigated the potential influence of a moderate-to-high cardiovascular (CV) risk (CVR) (defined as a Systematic
COronary Risk Evaluation model, or SCORE ≥ 4%), in the absence of an established CV disease, on the duration and cost
of CV and non-CV sick leave (SL) resulting from common and occupational accidents or diseases.
Methods
and results
We conducted a prospective cohort study on 690 135 workers with a 1-year follow-up and examined CV- and non-CV-
related SL episodes. To obtain baseline values, CVR factors were initially assessed at the beginning of theyear during routine
medicalexamination.TheCVRwascalculatedwith theSCOREcharts forall subjects.Moderate-to-highCVRwasdefinedas
SCORE ≥ 4%. A baseline SCORE ≥ 4% was associated with a higher risk for long-term CV and non-CV SL, as revealed by
follow-up assessment. This translated into an increased cost, estimated atE5 801 464.18 per year. Furthermore, pharma-
cological treatment for hypertension or hyperlipidaemia was significantly associated with longer SL duration.
Conclusion Moderate-to-high CVR in asymptomatic subjects was significantly associated with the duration and cost of CV and non-CV
SL. These results constitute the first body of evidence that the SCORE charts can be used to identify people with a non-
established CV disease, which might ultimately translate into more lost workdays and therefore increased cost for society.
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Introduction
An important component of the economic burden of cardiovascular
(CV) disease is the loss of productivity due to CV morbidity and pre-
mature death.1 Several factors are known to delay the return to work
following aCVevent, increasing the costofCV-related sick leave (SL).
Indeed, many CV risk (CVR) factors (e.g. hypertension,2 smoking,3
diabetes,4 obesity,5 risk factors collectively known as ‘metabolic syn-
drome’,6 and various health-related risk factors7) have been inde-
pendently and positively associated with SL duration and the costs
attributable to CV diseases. These data indicate that CVR factors
could have a significant, deleterious economic impact even before
overt CV disease is apparent.8 Therefore, the control of CVR
factors through lifestyle modification and/or pharmacological inter-
vention might not only help save lives, but may also reduce the
direct and indirect costs incurred as a result of lost productivity.9 –11
More than5 million SLepisodes are recordedannually in Spain, and
the cost of providing temporary sick pay benefits exceeds E6000
million annually.12 Thus, SL analysis is valuable not only for estimating
imputable costs, but also for identifying groups with increased health
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risks that are in need of targeted intervention.13 Routine medical
examination provides an opportunity for early screening of
workers for vascular risk factors and to select subjects with high
CVR for more intensive intervention.14,15
In this context, we investigated the relationship between global
CVR and the incidence, length, and cost of CV-disease-related SL.
In addition, we examined the role of CVR in SL resulting from
non-CV diseases and work-related accidents, which, to our knowl-
edge, has never been investigated.
The aim of this study was therefore to investigate the relationship
between global CVR, which was estimated using SCORE charts,16
and the 1-year incidence, length and cost of SL for CV-, non-CV-, or
work accident-related reasons. Specifically, we analysed a large, repre-
sentative sampleof the Spanish workforce to gain a better understand-
ing of the financial burdens associated with CVR in this group.
Methods
Study design and participants
This prospective cohort analysis was part of the ICARIA (Ibermutuamur
CArdiovascular RIsk Assessment) study.15 Ibermutuamur is a mutual in-
surance company for work-related accidents and occupational illnesses
that covers a population of approximately 1 million workers. Mutual in-
surance companies in Spain collaborate with National Social Security
to administer statutory sick pay. Their responsibility also includes provid-
ing health care in the event of work-related accidents or occupational ill-
nesses. In addition, a subsidiary company of Ibermutuamur (Sociedad de
Prevencio´n de Ibermutuamur) focuses specifically on preventing diseases
and accidents by monitoring and promoting the health of workers
through routine annual medical examination, among other things.
A total of 1 441 267 medical examinations were performed between
May 2004 and December 2007. However, only data from each subject’s
first examination, containing all relevant CVR information, were consid-
ered in the present study.A total of 690 135 subjects were included in this
study (71.6% male; mean ages: 36 for males and 34 for females; age range:
16–75). No significant socio-demographic differences (i.e. age, gender,
occupational sector, and geographical distribution) were detected
between workers who were included in the study and those who were
not (data not shown). Importantly, this population was representative
of the Spanish workforce.15 Records of physician-certified SL episodes
over a 1-year period were obtained from the Social Security Register
for SL due to common diseases and the Ibermutuamur Register for SL
due to work-related accidents. For SL episodes due to CV disease, the
ICD-917 codes 401–414 and 426–443 were considered, with the excep-
tion of codes 426.7, 429.0, 430.0, 432.1, 437.3, 437.4, and 437.5, which
relate to non-atherosclerotic causes of death. This corresponds to end-
points defined in the SCORE project.16
The SCORE chart is the most widely used European CVR assessment
tool and can be used to determine whether a subject is at high CVR
(10-year risk of CV death is ≥5%), moderate CVR (10-year risk of 4–
4.9%), or low CVR (10-year risk of ,4%).16,18 Additional information
regarding risk factor measurement and CVR classification in the
ICARIA study has been provided previously.15,18 Here, CV disease was
defined as a clinically documented diagnosis of coronary, cerebrovascu-
lar, or peripheral arterial disease. Workers with type 1 or type 2 diabetes
were excluded from this study.
The subjects weredivided into two agegroups (,45vs.≥45, the latter
representing approximately the upper 20th age percentile), and two oc-
cupational groups based on the Spanish National Classification of
Occupations [blue-collar (BC) workers and white-collar (WC)
workers].18 They were also classified according to smoking status
(smoker vs. non-smoker).15
Sick leave parameters
All 690 135 workerswere monitored for 1 yearafter the dateof their first
medical examination. Incidence, duration (days), and contribution basis
(in euro) were obtained for SL episodes caused by common CV-,
non-CV-, or work accident-related reasons. The total number of SL
days taken by each worker was then totalled and used as a dependent
variable in analyses focused on SL duration.
Ethical issues
Signed informed consent wasobtained fromall participants before enrol-
ment in the study, in accordance with the principles stated in the Declar-
ation of Helsinki. The protocol was reviewed and approved by the local
Ethics Committee.
Statistical analysis
All the statistical analyses were performed at the patient level. The annual
incidence of at least one SL episode caused by common non-CV diseases,
CV diseases, or work-related accidents was calculated separately in the
overall cohort, and according to each variable considered (gender, age,
occupation, smoking status, and CVR profile). Data were presented as
percentages with 95% confidence intervals. A x2 test was used to
compare the SL incidence between the groups. The median and respect-
ive 25th and 75th percentiles were calculated for SL duration. The differ-
ences in median duration between groups were evaluated with the
two-sample median test. Poisson regression was utilized for analysis of
the association between CVR and SL duration. Crude and adjusted rate
ratios (RRs) were calculated, adjusted by age, smoking status, or com-
bined variables (gender, age, occupation, and smoking status). In addition,
an over-dispersion correction for standard errors was performed. Fur-
thermore, data were calculated separately for CV diseases, non-CV dis-
eases, and work-related accidents. Categories with a lower median
duration forall variableswereusedas the reference. Finally, theeconomic
impactof longerSL durations inmoderate-to-high CVRworkers wasesti-
mated by multiplying the mean contribution basis of employees by the
estimated increase in SL days in subjects with moderate-to-high CVR,
and then by the number of workers in each SL group. Adjusted RRs
were used to estimate the increase in SL days in moderate-to-high
CVR with respect to the low CVR group, when such an association
remained significant after entering covariates in the Poisson regression
models. All analyses were performed using the SAS statistical package
(SAS v. 9.1, SAS Institute, Inc., Cary, NC, USA).
Results
Sick leave due to common
non-cardiovascular diseases
The incidence of SL caused by common non-CV diseases was 13.9%,
and the median duration of SL was 11 days (Table 1, Non-CV dis-
eases). Both incidence and duration were higher in women than in
men, in smokers than in non-smokers, and in BC than in WC
workers. Age ≥45 years was associated with a lower incidence but
longer duration of SL. Workers with moderate-to-high CVR had an
SL incidence that was not significantly different from low CVR indivi-
duals, but SL duration for moderate/high individuals was about twice
as long (median duration 18 vs. 11 days, P, 0.0001).
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Table 1 One-year incidence of at least one sick leave episode caused by common non-cardiovascular diseases,
work-related accidents, cardiovascular diseases, and sick leave duration (days) in a cohort of 690 135workers (overall study
population and data segmented by gender, age, smoking status, occupation, and cardiovascular risk profile)
Demographic, health, and
occupational variables
Numberofworkerswithat least
one sick leave episode
Incidencea (95%
CI)
P-valueb Median total duration
(P25;P75)
P-valuec
Non-cardiovascular diseases
Gender
Male 64 871 13.1 (12.1–14.05) ,0.0001 11 (5;28) ,0.0001
Female 31 376 16.1 (14.4–17.7) 13 (5;39)
Age (years)
,45 80 303 14.4 (13.5–15.3) ,0.0001 10 (5;28) ,0.0001
≥45 15 944 11.9 (10.2–13.6) 18 (7;58)
Smoking status
Smoker 51 465 15.5 (15.3–15.6) ,0.0001 11 (5;31) 0.0014
Non-smoker 44 782 12.5 (12.4–12.6) 11 (5;33)
Occupation
Blue collar 66 992 14.8 (13.7–15.8) ,0.0001 11 (5;32) 0.2636
White collar 29 255 12.2 (10.9–13.5) 11 (5;32)
Cardiovascular risk profile
Moderate to high 5391 12.8 (9.6–15.9) 0.42 18 (8;57) ,0.0001
Low 90 856 14.0 (13.1–14.8) 11 (5;31)
Total 96 247 13.9 (13.1–14.7) 11 (5;32)
Work-related accidents
Gender
Male 40 589 8.2 (7.4–8.9) ,0.0001 11 (6;25) ,0.0001
Female 6187 3.1 (2.3–3.9) 13 (7;28)
Age (years)
,45 38 634 6.9 (6.2–7.6) 0.04 11 (6;23) ,0.0001
≥45 8142 6.1 (4.8–7.3) 14 (7;36)
Smoking status
Smoker 27 912 8.38 (8.3–8.5) ,0.0001 11 (6;24) ,0.0001
Non-smoker 18 864 5.28 (5.2–5.4) 11 (6;27)
Occupation
Blue collar 42 541 9.4 (8.5–10.2) ,0.0001 11 (6;25) ,0.0001
White collar 4235 1.7 (1.2–2.3) 13 (6;29)
Cardiovascular risk profile
Moderate to high 2940 6.9 (4.5–9.4) 0.46 13 (7;34) ,0.0001
Low 43 836 6.7 (6.1–7.3) 11 (6;25)
Total 46 776 6.7 (6.1–7.3) 11 (6;25)
Cardiovascular diseases
Gender
Male 604 0.12 (0.10–0.14) ,0.0001 101.5 (31.5;235) 0.0011
Female 77 0.04 (0.03–0.05) 29 (12;153)
Age (years)
,45 252 0.05 (0.03–0.07) ,0.0001 54 (13;149.5) ,0.0001
≥45 429 0.32 (0.28–0.367) 122 (39;253)
Smoking status
Smoker 380 0.11 (0.09–0.13) ,0.0001 108.50 (33;249.50) 0.0403
Non-smoker 301 0.08 (0.06–0.10) 74 (19;191)
Occupation
Blue collar 502 0.11 (0.09–0.13) ,0.0001 96 (26;250) 0.3496
White collar 179 0.08 (0.06–0.10) 88 (25;174)
Continued
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Non-CV diseases causing SL episodes were mainly: (i) diseases of
the respiratory system (ICD 460–519); (ii) diseases of the musculo-
skeletal system and connective tissue (ICD 710–739); (iii) injury and
poisoning (ICD 800–999); (iv) poorly defined conditions (ICD 780–
799); (v) infectious or parasitic diseases (ICD 001–139); (vi) diseases
of the digestive system (ICD 520–579); (vii) mental disorders (ICD
290–319); (viii) and diseases of the nervous system and sense
organs (ICD 320–389). In each of these conditions, the median SL
duration was significantly longer in individuals with moderate-to-high
CVR than with low CVR.
Sick leave due to work-related accidents
The overall incidence of SL caused by work-related accidents (6.8%)
was significantly lower than that caused by common non-CV dis-
eases, but the median duration (11 days) was similar (Table 1, Work-
related accidents). The duration was slightly longer in women and
individuals ≥45 years, but not in smokers. On the other hand, BC
workers had a slightly shorter median duration of SL. Moreover,
moderate-to-high CVR was significantly associated with a longer
median duration of SL due to work-related accidents.
Sick leave due to common cardiovascular
diseases
As expected for the relatively young population of workers included
in the ICARIA study, the incidence of SL caused by common CV dis-
eases was very low (0.10%), i.e. much lower than the incidence of SL
due to non-CV diseases or to work-related accidents (Table 1, CV
diseases). The occurrence of CV-related SL was significantly higher
in men, individuals ≥45 years, smokers, and BC workers. Moreover,
the risk of SL due to CV disease for moderate-to-high CVR indivi-
duals, although rather low (0.66%), was .10 times higher than for
low CVR individuals (0.06%, P, 0.0001). On the other hand, the
median duration of CV-related SL was notably long (92 days), and sig-
nificantly longer in men, older workers, and smokers. The median SL
duration was also significantly greater for individuals at moderate/
high CVR than for individuals at low CVR.
Associationwith cardiovascular treatment
As shown in Table 2, 26% of workers with moderate-to-high CVR and
3% of those with low CVR were being treated for arterial hypertension
and/or hyperlipidaemia. The median duration of SL caused by common
non-CV diseases or work-related accidents for these treated patients
(both higher and lower CVR) was significantly longer than that of sub-
jects without pharmacological treatment (P, 0.0001 in all cases). A
similar trend was observed for CV-related SL, but the difference did
not reach statistical significance, likely because of the small sample
size. Finally, pharmacologically treatedpatientswereolder thanuntreat-
ed ones, with the age difference small in the moderate-to-high CVR
group (54.5+7.5 vs. 50.1+10.3; P, 0.0001) and more pronounced
in the low CVR group (47.7+8.7 vs. 34.1+9.7; P, 0.0001).
Role of associated variables
The results of the Poisson regression analyses for the association of
CVR with SL duration following covariate adjustment are presented
in Table 3. Moderate-to-high CVR was associated with a significant in-
crease in SL duration for CV or non-CV causes. Although the inclu-
sion of age in the model reduced the magnitude of the estimated
association between CVR and SL duration, the association remained
significant for all three SL categories. Results from models that also
adjusted for sex, occupation, and smoking status continued to
reveal a significant association between CVR and SL duration for SL
due to non-CV diseases and CV diseases, but no significant associ-
ation for work-related accidents.
Cost analysis
Estimates of the additional costs associated with increased SL taken
by individuals at higher CVR are summarized inTable4. We estimated
that the lengthened duration of non-CV-disease-related SL in indivi-
duals with moderate-to-high CVR amounted to additional costs of
E2 151 920.99, and that E3 649 543.19 would be due to overt CV
diseases, with a total additional cost of E5 801 464.18 during only
the first year following initial medical examination.
Discussion
The most important and novel finding of this study is that
moderate-to-high CVR was associated with an increased duration
and cost of SL caused by common non-CV diseases.
A separate analysis of single CVR factors or patient characteristics
demonstrated that many factors contributed to the increased dur-
ation of non-CV disease SL, confirming previously reported data.2 –
8 However, in our study, even though gender, age, occupation, and
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Table 1 Continued
Demographic, health, and
occupational variables
Numberofworkerswithat least
one sick leave episode
Incidencea (95%
CI)
P-valueb Median total duration
(P25;P75)
P-valuec
Cardiovascular risk profile
Moderate to high 278 0.66 (0.62–0.70) ,0.0001 111 (36;250) 0.0218
Low 403 0.06 (0.04–0.08) 79 (19;201)
Total 681 0.10 (0.09–0.11) 92 (26;225)
95% CI, 95% confidence interval; P25;P75, 25th and 75th percentiles.
aPercentage of individuals with at least one sick leave episode.
bP-value for x2 test.
cP-value for two-sample median test.
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smoking status were separately associated with SL incidence and dur-
ation, they did not completely account for the increased length of
non-CV-related SL when global CVR was elevated. Thus, our
results indicate that the SCORE charts identify workers with non-
established CV disease that might contribute to increased lost work-
days, and therefore higher cost for society. On the other hand,
increased duration of SL due to work accidents in subjects with
moderate-to-high CVR disappeared after adjusting for covariates.
To our knowledge, this prospective cohort study is the first to es-
timate the difference in costs associated with SL in workers with a
moderate-to-high global CVR compared with those with a low
CVR. Altogether, our study revealed an approximate increase in
SL-associated cost (due primarily to SL caused by CV and non-CV
common diseases in males) of E5 801 464.18 in the year after
initial medical examination. When extrapolated to the total active
Spanish workforce, this cost can be estimated at about E145
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Table2 Numberofworkerswith at least one sick leaveepisode causedbya commondiseaseorwork-related accident for
non-cardiovascular reasonsordue to cardiovascular diseases and sick leaveduration inworkerswithmoderate-to-high and
lowcardiovascular risk,with orwithout treatment for hypertension and/or hyperlipidaemia, in acohort of 690 135workers
with a 1-year follow-up
Cardiovascular risk With or without
treatment
Number of workers
with at least one
sick leave episode
Median
total
duration
P25;P75 P-valueb
Common disease
Moderate to high With treatment 1393 20 8;64 ,0.0001
Without treatment 3998 18 7;53
Low With treatment 2805 17 7;52 ,0.0001
Without treatment 88 051 11 5;30
Work-related accident
Moderate to high With treatment 652 16 7;39.5 ,0.0001
Without treatment 2288 13 7;33
Low With treatment 1307 13 6;32 ,0.0001
Without treatment 42 529 11 6;24
Cardiovascular diseases
Moderate to high With treatment 125 106 36;257 0.7121
Without treatment 139 115 36;250
Low With treatment 68 102 30;239.5 0.2844
Without treatment 308 73 18.5;184.5
P25;P75, 25th and 75th percentiles.
aP-value for two-sample median test.
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Table 3 Crude and adjusted association between cardiovascular risk and sick leave duration caused by a commondisease
or work-related accident for non-cardiovascular reasons or due to cardiovascular diseases, calculated with a Poisson
regression model (Poisson regression, stepwise adjusted model)
Cardiovascular risk Model I: crude Model II: adjusted by age Model III: adjusted by sex, age,
occupation, and smoking status
RR 95% CI P-value RR 95% CI P-value RR 95% CI P-value
Common disease
Moderate to high 1.58 1.51–1.67 ,0.0001 1.21 1.15–1.28 ,0.0001 1.23 1.17–1.30 ,0.0001
Low 1 1 1
Work-related accident
Moderate to high 1.43 1.32–1.54 ,0.0001 1.23 1.14–1.34 ,0.0001 0.97 0.90–1.04 0.3855
Low 1 1 1
Cardiovascular diseases
Moderate to high 12.68 10.18–15.80 ,0.0001 3.74 2.92–4.81 ,0.0001 2.80 2.14–3.67 ,0.0001
Low 1 1 1
RR, rate ratio; 95% CI, 95% confidence interval.
Poisson regression model; RR , 1 indicates a shorter sick leave duration; RR . 1 indicates a longer sick leave duration.
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million per year. Moreover, our data estimated an increased cost
associated with the early stages of CV disease in people with a
SCORE ≥4%, and indicated that these costs are partly unrelated to
SL for CV disease. In addition to CV diseases, these heightened
costs could result from increased SL caused by other types of
non-CV diseases (e.g. respiratory, gastrointestinal, musculoskeletal,
or infectious).
The reasons for this association between increased global CVR
and longer duration of non-CV-related SL are unclear. The subjects
included in the ICARIA study were relatively young (mean age of
36 years), and only 20% of them were ≥45 years old. In addition,
even those with a higher CVR level were unlikely to develop a con-
sistent number of CV complications within the first year following
initial examination, and this could explain the paucity of SL episodes
attributed to CV diseases in the ICARIA cohort. Furthermore, some
CVR factors, such as age and smoking, are also linked to a number of
non-CV diseases. However, although these risk factors (especially
age) appeared to play some role, adjusting for these and other
CVR factors could not entirely account for the association
between global CVR and non-CV disease SL duration. We can
propose two distinct hypotheses that could explain this association.
First, increased CVR may signify a broader general risk for common
diseases, including non-CV-related illnesses, since higher CVR can in-
dicate frailer individuals. This may be due to the fact that CVR is often
associated with pro-inflammatory or pro-thrombotic states,19,20
which are also known to contribute to a number of non-CV diseases
(e.g. respiratory diseases, musculoskeletal pathology, or infectious
diseases). Thus, it is important to note that both CV diseases and a
wide range of common non-CV diseases are rooted in the same clus-
ters of health risk behaviours, which have become prominent in the
Western world. Moreover, voluntary risk exposure, such as smoking,
could be indicative of a risky personality type, and individuals who
would regularly engage in such unsafe conduct may be more likely
to be exposed to additional lifestyle-related hazards (e.g. risky
sports, unsafe driving habits, and/or multiple sexual partners).21
A second hypothesis that could account for the association
between CVR and non-CV-related SL duration involves a patient’s
growing awareness of their CVR. It is possible that becoming labelled
as high risk for CV disease ultimately leads to a protective response in
some individuals, who increase their number of SL episodes or elect
longer SL durations. In this regard, we would like to point out that
patients who were noted as having low or moderate/high CVR,
and who were prescribed CV drug treatment (BP lowering or lipid
lowering), had significantly longer SL due to non-CV diseases or
work-related accidents. However, this observation is not entirely un-
expected, as it is well known from prospective observational studies
that hypertensive patients receiving treatment have a higher
outcome incidence than untreated hypertensive patients,22– 24
even though this directly contradicts data from controlled, rando-
mized trials that consistently show outcome reduction by antihyper-
tensive therapy.25 These discrepancies are thought to result from the
fact that, in clinical practice, hypertensive patients areprescribed drug
treatment when their global risk is elevated, whereas lower global
risk hypertensive patients are often left untreated. This habit is con-
sistent with the existing guidelines,26 and with the reimbursement
policies of some national health services, which only reimburse anti-
hypertensive drugs or statins to patients with a high global CVR.
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Indeed, in the ICARIA study, workers under CV treatment were
older than untreated workers. However, among moderate-to-high
CVR individuals, age difference was rather small (54 vs. 50 years),
and is unlikely to be the main factor causing the difference in SL dur-
ation. It is, therefore, plausible that, in the ICARIA study, workers re-
ceiving CV drugs were in the upper part of the CVR range in which
they had been classified, which obscured beneficial treatment
effects and justified longer SL periods. Furthermore, regarding CVR
awareness, receiving a drug prescription for CV reasons is likely to
elicit a greater worry response from patients. Finally, but less prob-
able, adverse effects due to drug treatment may lengthen SL duration.
In conclusion, our study shows that a higher level of CVR increases
the duration of SL, due not only to CV diseases, but also to common
non-CV diseases. Thus, CVR contributes to a marked increase in the
financial burden resulting from SL, which we have calculated as
E5 801 464.18 in 1 year for the 690 135 workers included in our
study.The obvious conclusion is that workplace preventive measures
aimed at early control of CVR27 may be widely beneficial in terms of
health since they likely influence non-CV diseases as well. Ultimately,
this could decrease the financial burden on society by reducing SL
duration. Moreover, the notion that labelling a patient as higher
CVR may cause concern, which consequently lengthens rather
than reduces SL duration, should not deter prevention. Instead, this
idea should promote the continued development of patient and em-
ployee education initiatives to communicate health information
moreprecisely toworkers. However, becauseour studywasonlyob-
servational, these inferences should be appropriately tested in an
interventional study.
Advantages and limitations
The key advantages of this study were the prospective design, the
sample size (approximately 700 000 workers of both genders in all
occupational sectors), and the analysis of various types of SL,
namely those caused by non-CV diseases, CV diseases, and work-
related accidents.
Regarding study limitations, although the ICARIA cohort could be
representative of the Spanish workforce,15 the generalizability of our
results should be tested in other countries. Additionally, the SCORE
charts present some limitations, such as overestimation of CVR in
individuals≥65 years of age, underestimation of CVR in younger indi-
viduals, and exclusion of variables (e.g. family history of early onset
coronary heart disease, impaired glucose tolerance, and hypertrigly-
ceridaemia). Nevertheless, the SCORE charts are widely used to cal-
culate CVR, and have been validated and calibrated in Spain.28
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Assessment of the vortex flow in the post-stenotic dilatation above the
pulmonary valve stenosis in an infant using echocardiography vector flow
mapping
Takashi Honda1†, Keiichi Itatani2,3*†, Kagami Miyaji2, and Masahiro Ishii1
1Department of Pediatrics, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; 2Department of Cardiovascular Surgery, Kitasato University School of Medicine,
Sagamihara, Kanagawa, Japan; and 3Department of Hemodynamic Analysis, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
* Corresponding author. Departments of Cardiovascular Surgery and Hemodynamic Analysis, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara,
Kanagawa 252-0374, Japan. Tel: +81-42-778-8829, Fax: +81-42-778-8441, Email: keiichiitatani@gmail.com
† T.H. and K.I. contributed equally to this work.
A 15-month-old male diagnosed with double outlet
right ventricle (DORV)suffered from right ventricu-
lar failure 8 months after DORV repair. The motion
of the anterior cusp of the pulmonary valve (PV)
after the commissurotomy of the bucuspid valve
was poor on echocardiography, and computed
tomography showed post-stenotic dilatation
(Panels A and B). We assessed the blood flow in
the post-stenotic dilatation site of the main pulmon-
ary artery (mPA) using echocardiography vector
flow mapping (VFM). VFM is a new technology
that makes it possible to visualize the flow velocity
vector, and to calculate energy loss (EL) which
results from the viscous dissipation in turbulent
blood flow using colour Doppler mapping and
speckle tracking and is thought to be the ventricular
workload. The flow velocity vector analysis clearly
showed that a large vortex formed from the poster-
ior wall to the anterior wall just above the PV, and
high EL was detected even though no pressure
drop was detected by catheterization (Panels C
and D). After PV plasty with commissurotomy, the
vortex diminished, resulting in a decrease of the
mPA diameter. Additionally, the EL level at the
mPA during the systolic phase considerably
decreased after the procedure (Panels E–G). In the present case, the flow vector analysis visualized the abnormalities of blood flow
above the PV stenosis. In addition, although further accumulation of such cases is warranted, EL would be a novel parameter that can
be used to quantitatively evaluate the pressure overload for the ventricles caused by stenotic lesions.
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